Exosome-derived microRNA-22 ameliorates pulmonary fibrosis by regulating fibroblast-to-myofibroblast differentiation both in vitro and in vivo.
BackgroundAlthough aberrant proliferation and activation of lung fibroblasts are implicated in the initiation and progression of idiopathic pulmonary fibrosis (IPF), the underlying mechanisms are not well characterized. Numerous microRNAs (miRNAs) have been implicated in this process; however, miRNAs derived from exosomes and their relevance to fibroblast-to-myofibroblast differentiation have not been fully elucidated. In this study, we aimed to identify exosome-derived miRNAs relevant to fibrosis development.MethodsWe profiled exosome-derived miRNAs expression in sera of C57BL/6 mice exhibiting bleomycin-induced pulmonary fibrosis by miRNA array analysis. After validating a selected miRNA by quantitative reverse-transcription polymerase chain reaction, its effect on fibroblast- to-myofibroblast differentiation was investigated using human lung fibroblasts. Furthermore, we determined the role of the selected miRNA in an in-vivo pulmonary fibrosis model.ResultsMiRNA array analysis revealed that miR-22 expression was increased by up to 2 fold on day 7 after bleomycin treatment compared with that in vehicle-treated mice. In vitro, miR-22 transfectionsuppressed TGF-β1-induced α-SMA expression. This was mediated via the inhibition of the ERK1/2 pathway. Baseline α-SMA expression was increased upon miR-22 inhibitor transfection. Furthermore, miR-22 negatively regulated connective tissue growth factor expression in the presence of TGF-β1. In vivo, administration of a miR-22 mimic on day 10 after bleomycin challenge ameliorated pulmonary fibrosis lesions accompanied by decreased α-SMA expression in the model mice.ConclusionsExosomal miR-22 modulates fibroblast-to-myofibroblast differentiation. The present study warrants further investigations to shed light on miR-22 as a novel therapeutic target for patients with IPF.